Electronic Drug Delivery Systems Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The global Electronic Drug Delivery Systems Market encompasses devices that utilize electronic mechanisms, sensors, and connectivity to administer medications with precision and programmable dosing. Valued at approximately $12.12 billion in 2025, the market is projected to reach between $19.44 billion and $20.19 billion by 2030, depending on scope and methodology across industry analyses. This represents a subset of the broader drug delivery devices market, which encompasses all delivery technologies and is valued at over $250 billion globally.

• •The market is positioned within the larger $47.72 billion global drug delivery systems market and the broader $261 billion drug delivery devices market
• •Industry estimates for 2025-2030 vary, with CAGRs ranging from 8.5% to 10.4% and 2030 projections between $19.44 billion and $20.19 billion
• •Electronic systems specifically represent a technology-intensive segment distinct from mechanical and manual delivery devices

The rising global prevalence of chronic diseases such as diabetes, asthma, rheumatoid arthritis, and multiple sclerosis is a primary driver, as these conditions require frequent and precise medication administration. The growing pipeline of biologic and specialty drugs, many of which cannot be formulated for oral delivery, necessitates advanced electronic delivery systems that ensure accurate dosing and patient adherence. Additionally, aging populations and increasing healthcare spending in emerging markets are expanding demand for sophisticated drug delivery solutions.

• •Rising incidence of diabetes and other chronic conditions drives demand for connected insulin pens and wearable injectors
• •Biologic drug growth requires precise dosing mechanisms that electronic systems uniquely provide
• •Healthcare cost pressures favor self-administration and home-based care enabled by electronic delivery devices

Electronic drug delivery systems include product categories such as autoinjectors, insulin pens, wearable injectors, smart infusion pumps, and needle-free systems. Geographically, North America dominates the market due to high healthcare spending, favorable reimbursement policies, and strong pharmaceutical R&D activity, while Europe represents the second-largest region. The U.S. electronic drug delivery devices segment alone is estimated at approximately $25.8 billion in 2025, reflecting the concentration of advanced therapies and technology adoption in that market.

• •North America leads the global market, supported by robust pharmaceutical innovation and healthcare infrastructure
• •The U.S. segment alone accounts for roughly double the total estimated global electronic systems market value under some scopes, suggesting scope differences in market definitions
• •Asia-Pacific is expected to be the fastest-growing regional market due to improving healthcare access and rising chronic disease burden

What are the recent trends and outlook?

Connectivity and digital integration are defining trends, with an increasing share of electronic delivery devices incorporating Bluetooth, mobile applications, and cloud-based data platforms to enable remote monitoring and personalized therapy adjustments. Wearable injectors and patch pumps are gaining traction as patient preference shifts toward less invasive and more discreet administration methods. The market is expected to continue its trajectory through 2030, with the total addressable opportunity potentially reaching $20 billion as biosimilars expand and personalized medicine drives demand for programmable, data-rich delivery platforms.

• •Connected devices with mobile app integration and data analytics capabilities are becoming the new standard in electronic delivery
• •Wearable injector technology is expanding beyond insulin into therapeutic areas such as immunology and oncology
• •Personalized medicine trends are accelerating demand for electronically controlled, dose-titratable delivery platforms